Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Green

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
BMJ (Clinical Research Ed.)|September 10, 2020
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality ScoreStephen R Knight, Antonia Ho, Riinu Pius, et al.
Thorax|November 23, 2021
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation ProtocolStephen R Knight, Rishi K Gupta, Antonia Ho, et al.
JAMA|January 24, 2022
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical TrialGavin D Perkins, Chen Ji, Bronwen A Connolly, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|January 14, 2021
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort studyRishi K Gupta, Ewen M Harrison, Antonia Ho, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
BMJ (Clinical Research Ed.)|September 10, 2020
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality ScoreStephen R Knight, Antonia Ho, Riinu Pius, et al.
Thorax|November 23, 2021
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation ProtocolStephen R Knight, Rishi K Gupta, Antonia Ho, et al.
JAMA|January 24, 2022
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical TrialGavin D Perkins, Chen Ji, Bronwen A Connolly, et al.
Lancet (London, England)|August 9, 2021
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialXinxue Liu, Robert H Shaw, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|June 11, 2022
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRobert H Shaw, Xinxue Liu, Arabella S V Stuart, et al.
The Journal of Infection|April 7, 2023
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccinesRobert H Shaw, Melanie Greenland, Arabella S V Stuart, et al.
The Lancet. Respiratory Medicine|January 14, 2021
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort studyRishi K Gupta, Ewen M Harrison, Antonia Ho, et al.
Lancet (London, England)|December 9, 2021
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialArabella S V Stuart, Robert H Shaw, Xinxue Liu, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 5